GLOBAL IMMUNOHISTOCHEMISTRY MARKET 2019-2027

MARKET OUTLOOK
The global immunohistochemistry market is projected to progress with 7.11% of CAGR over the forecast period of 2019-2027.
This market is driven by the global rise in cancer cases, rapidly growing aging population, development in healthcare infrastructure and the increasing healthcare expenditure. However, factors such as reimbursement issues, restrictions of systems and the population with zero insurance coverage are being viewed as hurdles in the growth of the immunohistochemistry industry. Some of the challenges faced by the immunohistochemistry market are the rigid rules & regulations and the additional costs of maintenance. However, the market giants can grasp key opportunities such as the developments in the field of technological healthcare and the diagnosis of diseases by using biomarkers to establish their base.
The global immunohistochemistry market is segmented on the basis of products, application and end-users. The product segment is further divided into antibodies, equipment, reagents and kits. The application segment consists of diagnostics and drug testing division. The end-users are further classified into subdivisions such as hospitals & diagnostic laboratories, research institutes and other end-users.
REGIONAL OUTLOOK
North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa are the regional segments of the global immunohistochemistry market. Presently, the North American immunohistochemistry market leads the global scenario. The demand for quality healthcare backed by high healthcare expenditure acts as a primary driver for the growth of the IHC market in the region. However, it is the Asia-Pacific market region that is expected to progress significantly in terms of CAGR over the forecast period.
COMPETITIVE OUTLOOK
Major players that are involved in this market include Bio SB, Merck Millipore, Agilent Technologies, Inc., Abcam Plc, PerkinElmer, Inc., F. Hoffmann-La Roche AG, Histologix, Bio-Rad Laboratories, Inc., Danaher Corporation, BioGenex, Thermo Fisher Scientific, Inc., Abbott Laboratories, Siemens AG Healthcare and Cell Signaling Technology, Inc.
Abcam operates in the field of life sciences and focuses mainly on offering web-based antibodies with comprehensive data. The company’s focus and strategies lie in R&D, acquisitions and partnerships. Abcam’s product portfolio comprises of antibodies, research-grade antibodies, IVD antibodies, proteins and peptides, etc. In November 2015, Abcam acquired AxioMx to discover new growth avenues and expand in the field of antibodies. In Aug-2017, the company collaborated with TTP Labtech to develop sol-R reagent kits.

TABLE OF CONTENT
1. IMMUNOHISTOCHEMISTRY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. HISTORY OF IMMUNOHISTOCHEMISTRY
2.3. VALUE CHAIN OUTLOOK
2.4. KEY INSIGHTS
2.5. REGULATORY OUTLOOK
2.5.1. REGULATIONS IN THE UNITED STATES
2.6. MARKET ATTRACTIVENESS MATRIX
2.7. MARKET DRIVERS
2.7.1. IN-VITRO TECHNOLOGICAL ADVANCEMENTS
2.7.2. INCREASING CANCER OCCURRENCE
2.7.3. SWELLING HEALTHCARE SPENDING
2.7.4. RISING GERIATRIC POPULATION
2.7.5. INCREASING USE OF POC TESTING
2.8. MARKET RESTRAINTS
2.8.1. RESTRICTIONS OF CLOSED SYSTEMS
2.8.2. REIMBURSEMENT ISSUES
2.9. MARKET OPPORTUNITIES
2.9.1. INCREASING USE OF BIOMARKERS FOR DISEASE DIAGNOSIS
2.9.2. TECHNOLOGICAL ADVANCEMENTS
2.10. MARKET CHALLENGES
2.10.1. STRINGENT REGULATIONS
2.10.2. HIGH MAINTENANCE COST INFLUENCING THE MARKET GROWTH
3. IMMUNOHISTOCHEMISTRY (IHC) MARKET OUTLOOK - BY PRODUCTS
3.1. ANTIBODIES
3.1.1. PRIMARY ANTIBODIES
3.1.2. SECONDARY ANTIBODIES
3.2. EQUIPMENT
3.2.1. SLIDE STAINING SYSTEMS
3.2.2. TISSUE MICROARRAYS
3.2.3. TISSUE PROCESSING SYSTEMS
3.2.4. SLIDE SCANNERS
3.2.5. OTHER EQUIPMENT
3.3. REAGENTS
3.3.1. HISTOLOGICAL STAINS
3.3.2. BLOCKING SERA AND REAGENTS
3.3.3. CHROMOGENIC SUBSTRATES
3.3.4. FIXATION REAGENTS
3.3.5. STABILIZERS
3.3.6. ORGANIC SOLVENTS
3.3.7. PROTEOLYTIC ENZYMES
3.3.8. DILUENTS
3.4. KITS
4. IMMUNOHISTOCHEMISTRY (IHC) MARKET OUTLOOK - BY APPLICATIONS
4.1. DIAGNOSTICS
4.1.1. CANCER
4.1.2. INFECTIOUS DISEASES
4.1.3. CARDIOVASCULAR DISEASE
4.1.4. AUTOIMMUNE DISEASES
4.1.5. DIABETES MELLITUS
4.1.6. NEPHROLOGICAL DISEASES
4.2. DRUG TESTING
5. IMMUNOHISTOCHEMISTRY (IHC) MARKET OUTLOOK - BY END-USERS
5.1. HOSPITALS AND DIAGNOSTIC LABORATORIES
5.2. RESEARCH INSTITUTES
5.3. OTHER END-USERS
6. IMMUNOHISTOCHEMISTRY (IHC) MARKET - REGIONAL OUTLOOK
6.1. NORTH AMERICA
6.1.1. MARKET BY PRODUCTS
6.1.2. MARKET BY APPLICATIONS
6.1.3. MARKET BY END-USERS
6.1.4. COUNTRY ANALYSIS
6.1.4.1. THE UNITED STATES
6.1.4.2. CANADA
6.2. EUROPE
6.2.1. MARKET BY PRODUCTS
6.2.2. MARKET BY APPLICATIONS
6.2.3. MARKET BY END-USERS
6.2.4. COUNTRY ANALYSIS
6.2.4.1. THE UNITED KINGDOM
6.2.4.2. FRANCE
6.2.4.3. GERMANY
6.2.4.4. SPAIN
6.2.4.5. ITALY
6.2.4.6. RUSSIA
6.2.4.7. REST OF EUROPE
6.3. ASIA-PACIFIC
6.3.1. MARKET BY PRODUCTS
6.3.2. MARKET BY APPLICATIONS
6.3.3. MARKET BY END-USERS
6.3.4. COUNTRY ANALYSIS
6.3.4.1. CHINA
6.3.4.2. INDIA
6.3.4.3. JAPAN
6.3.4.4. SOUTH KOREA
6.3.4.5. AUSTRALIA & NEW ZEALAND
6.3.4.6. ASEAN COUNTRIES
6.3.4.7. REST OF APAC
6.4. LATIN AMERICA
6.4.1. MARKET BY PRODUCTS
6.4.2. MARKET BY APPLICATIONS
6.4.3. MARKET BY END-USERS
6.4.4. COUNTRY ANALYSIS
6.4.4.1. BRAZIL
6.4.4.2. MEXICO
6.4.4.3. ARGENTINA
6.4.4.4. CHILE
6.4.4.5. CUBA
6.4.4.6. REST OF LATIN AMERICA
6.5. MIDDLE EAST AND AFRICA
6.5.1. MARKET BY PRODUCTS
6.5.2. MARKET BY APPLICATIONS
6.5.3. MARKET BY END-USERS
6.5.4. COUNTRY ANALYSIS
6.5.4.1. SAUDI ARABIA
6.5.4.2. TURKEY
6.5.4.3. UNITED ARAB EMIRATES
6.5.4.4. SOUTH AFRICA
6.5.4.5. REST OF MIDDLE EAST AND AFRICA
7. COMPETITIVE LANDSCAPE
7.1. ABBOTT LABORATORIES
7.2. ABCAM PLC
7.3. AGILENT TECHNOLOGIES, INC.
7.4. BIOGENEX
7.5. BIO-RAD LABORATORIES, INC.
7.6. BIO SB
7.7. CELL SIGNALING TECHNOLOGY, INC.
7.8. DANAHER CORPORATION
7.9. F. HOFFMANN-LA ROCHE AG
7.10. HISTOLOGIX
7.11. MERCK MILLIPORE
7.12. PERKINELMER, INC.
7.13. SIEMENS AG HEALTHCARE
7.14. THERMO FISHER SCIENTIFIC, INC.
8. METHODOLOGY AND SCOPE
8.1. RESEARCH SCOPE
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY




TABLE LIST
TABLE 1 GLOBAL MARKET FOR IMMUNOHISTOCHEMISTRY BY REGION 2019-2027 ($ MILLION)
TABLE 2 ANTIBODY MANUFACTURERS IN THE GLOBAL IMMUNOHISTOCHEMISTRY MARKET
TABLE 3 CANCER MARKERS USED IN DIAGNOSIS AND TREATMENT
TABLE 4 POPULATION AGED 60 YEARS AND ABOVE
TABLE 5 POPULATION AGED 80 YEARS AND ABOVE
TABLE 6 COUNTRIES WITH THE HIGHEST NUMBER OF ELDERLY PEOPLE
TABLE 7 GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY PRODUCTS 2019-2027 ($ MILLION)
TABLE 8 INCIDENCE OF DIABETES IN MAJOR COUNTRIES 2016 ($ MILLION)
TABLE 9 CLINICALLY IMPORTANT MONOCLONAL ANTIBODIES
TABLE 10 SECONDARY ANTIBODY SELECTION
TABLE 11 GLOBAL IMMUNOHISTOCHEMISTRY MARKET IN EQUIPMENT BY TYPES 2019-2027 ($ MILLION)
TABLE 12 HEALTHCARE SPENDING BY HIGH-INCOME COUNTRIES BY 2040
TABLE 13 GLOBAL IMMUNOHISTOCHEMISTRY MARKET IN REAGENTS BY TYPE 2019-2027 ($ MILLION)
TABLE 14 HISTOLOGY STAINS AND ITS CATEGORIES
TABLE 15 COMMON FIXATIVES AND THEIR GENERAL TARGET ANTIGENS
TABLE 16 KIT COMPONENTS ARE AVAILABLE FOR IHC OPTIMIZATION
TABLE 17 GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 18 GLOBAL IMMUNOHISTOCHEMISTRY MARKET IN DIAGNOSTICS BY TYPE 2019-2027 ($ MILLION)
TABLE 19 SELECTED INFECTIOUS ETIOLOGIES OF AUTOIMMUNE DISEASES
TABLE 20 GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY END-USERS 2019-2027 ($ MILLION)
TABLE 21 CANCER RESEARCH PROGRAM
TABLE 22 IMMUNOHISTOCHEMISTRY USAGE IN FORENSIC PATHOLOGY
TABLE 23 GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 24 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY PRODUCTS 2019-2027 ($ MILLION)
TABLE 25 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY APPLICATIONS 2019-2027 ($ MILLION)
TABLE 26 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY END-USERS 2019-2027 ($ MILLION)
TABLE 27 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 28 FUNDS INVESTED FOR DIFFERENT CANCER TYPES (2017)
TABLE 29 PERCENT DISTRIBUTION OF PROJECTED NEW CANCER CASES (2017)
TABLE 30 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY PRODUCTS 2019-2027 ($ MILLION)
TABLE 31 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY APPLICATIONS 2019-2027 ($ MILLION)
TABLE 32 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY END-USERS 2019-2027 ($ MILLION)
TABLE 33 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 34 NUMBER OF PEOPLE LIVING AND DYING WITH CVD
TABLE 35 NUMBER OF DEATHS CAUSED BY CARDIOVASCULAR DISEASES IN GERMANY 2016
TABLE 36 DISEASES CAUSING PREMATURE DEATH IN GERMANY (2017)
TABLE 37 ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET BY PRODUCTS 2019-2027 ($ MILLION)
TABLE 38 ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET BY APPLICATIONS 2019-2027 ($ MILLION)
TABLE 39 ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET BY END-USERS 2019-2027 ($ MILLION)
TABLE 40 ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 41 CANCER TYPES BASED ON INCIDENCE RATES (2016)
TABLE 42 CANCER TYPES BASED ON MORTALITY RATES (2016)
TABLE 43 ESTIMATED INCIDENCE OF ALL CANCERS COMBINED BY SEX (2017)
TABLE 44 ESTIMATED COMMON CAUSES OF DEATH FOR CANCER (MALES 2017)
TABLE 45 ESTIMATED COMMON CAUSES OF DEATH FOR CANCER BY SEX (FEMALES 2017)
TABLE 46 LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
TABLE 47 LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET BY PRODUCTS 2019-2027 ($ MILLION)
TABLE 48 LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET BY APPLICATIONS 2019-2027 ($ MILLION)
TABLE 49 LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET BY END-USERS 2019-2027 ($ MILLION)
TABLE 50 LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 51 CAUSES OF DEATH IN ARGENTINA 2016
TABLE 52 CAUSES OF DEATH IN CUBA 2016
TABLE 53 MIDDLE EAST AND AFRICA IMMUNOHISTOCHEMISTRY MARKET BY PRODUCTS 2019-2027 ($ MILLION)
TABLE 54 MIDDLE EAST AND AFRICA IMMUNOHISTOCHEMISTRY MARKET BY APPLICATIONS 2019-2027 ($ MILLION)
TABLE 55 MIDDLE EAST AND AFRICA IMMUNOHISTOCHEMISTRY MARKET BY END-USERS 2019-2027 ($ MILLION)
TABLE 56 MIDDLE EAST AND AFRICA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY 2019-2027 ($ MILLION)



FIGURE LIST
FIGURE 1 GLOBAL MARKET FOR IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 2 HISTORY OF IMMUNOHISTOCHEMISTRY
FIGURE 3 GLOBAL IMMUNOHISTOCHEMISTRY MARKET IN ANTIBODIES 2019-2027 ($ MILLION)
FIGURE 4 GLOBAL ANTIBODIES MARKET IN PRIMARY ANTIBODIES BY REGION 2019-2027 ($ MILLION)
FIGURE 5 GLOBAL ANTIBODIES MARKET IN SECONDARY ANTIBODIES REGION 2019-2027 ($ MILLION)
FIGURE 6 GLOBAL IMMUNOHISTOCHEMISTRY MARKET IN EQUIPMENT 2019-2027 ($ MILLION)
FIGURE 7 GLOBAL EQUIPMENT MARKET IN SLIDE STAINING SYSTEMS BY REGION 2019-2027 ($ MILLION)
FIGURE 8 GLOBAL EQUIPMENT MARKET IN TISSUE MICROARRAYS BY REGION 2019-2027 ($ MILLION)
FIGURE 9 GLOBAL EQUIPMENT MARKET IN TISSUE PROCESSING SYSTEMS BY REGION 2019-2027 ($ MILLION)
FIGURE 10 GLOBAL EQUIPMENT MARKET IN SLIDE SCANNERS BY REGION 2019-2027 ($ MILLION)
FIGURE 11 GLOBAL EQUIPMENT MARKET IN OTHER EQUIPMENT BY REGION 2019-2027 ($ MILLION)
FIGURE 12 GLOBAL IMMUNOHISTOCHEMISTRY MARKET IN REAGENTS 2019-2027 ($ MILLION)
FIGURE 13 GLOBAL REAGENTS MARKET IN HISTOLOGICAL STAINS BY REGION 2019-2027 ($ MILLION)
FIGURE 14 GLOBAL REAGENTS MARKET IN BLOCKING SERA AND REAGENTS BY REGION 2019-2027 ($ MILLION)
FIGURE 15 GLOBAL REAGENTS MARKET IN CHROMOGENIC SUBSTRATES BY REGION 2019-2027 ($ MILLION)
FIGURE 16 GLOBAL REAGENTS MARKET IN FIXATION REAGENTS BY REGION 2019-2027 ($ MILLION)
FIGURE 17 GLOBAL REAGENTS MARKET IN STABILIZERS BY REGION 2019-2027 ($ MILLION)
FIGURE 18 GLOBAL REAGENTS MARKET IN ORGANIC SOLVENTS BY REGION 2019-2027 ($ MILLION)
FIGURE 19 GLOBAL REAGENTS MARKET IN PROTEOLYTIC ENZYMES BY REGION 2019-2027 ($ MILLION)
FIGURE 20 GLOBAL REAGENTS MARKET IN DILUENTS BY REGION 2019-2027 ($ MILLION)
FIGURE 21 PHASES OF HISTOLOGICAL STAINING
FIGURE 22 GLOBAL IMMUNOHISTOCHEMISTRY MARKET IN KITS 2019-2027 ($ MILLION)
FIGURE 23 GLOBAL IMMUNOHISTOCHEMISTRY MARKET IN DIAGNOSTICS 2019-2027 ($ MILLION)
FIGURE 24 GLOBAL DIAGNOSTICS MARKET IN CANCER BY REGION 2019-2027 ($ MILLION)
FIGURE 25 DIAGNOSTICS MARKET IN CARDIOVASCULAR DISEASE BY REGION 2019-2027 ($ MILLION)
FIGURE 26 GLOBAL DIAGNOSTICS MARKET IN AUTOIMMUNE DISEASES BY REGION 2019-2027 ($ MILLION)
FIGURE 27 GLOBAL DIAGNOSTICS MARKET IN DIABETES MELLITUS BY REGION 2019-2027 ($ MILLION)
FIGURE 28 GLOBAL DIAGNOSTICS MARKET IN NEPHROLOGICAL DISEASES BY REGION 2019-2027 ($ MILLION)
FIGURE 29 HEALTHCARE EXPENDITURES ACROSS THE GLOBE (% OF GDP)
FIGURE 30 GLOBAL PREVALENCE OF CHRONIC KIDNEY DISEASES BY AGE
FIGURE 31 GLOBAL IMMUNOHISTOCHEMISTRY MARKET IN DRUG TESTING 2019-2027 ($ MILLION)
FIGURE 32 INCIDENCE OF PATIENTS WITH CHRONIC DISEASES GLOBALLY 2005-2030
FIGURE 33 GLOBAL IMMUNOHISTOCHEMISTRY MARKET IN HOSPITALS AND DIAGNOSTIC LABORATORIES 2019-2027 ($ MILLION)
FIGURE 34 GLOBAL IMMUNOHISTOCHEMISTRY MARKET IN RESEARCH INSTITUTES 2019-2027 ($ MILLION)
FIGURE 35 GLOBAL IMMUNOHISTOCHEMISTRY MARKET IN OTHER END-USERS 2019-2027 ($ MILLION)
FIGURE 36 NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 37 THE UNITED STATES IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 38 CANADA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 39 EUROPE IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 40 THE UNITED KINGDOM IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 41 FRANCE IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 42 GERMANY IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 43 SPAIN IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 44 ITALY IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 45 RUSSIA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 46 REST OF EUROPE IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 47 ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 48 CHINA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 49 INDIA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 50 JAPAN IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 51 SOUTH KOREA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 52 AUSTRALIA & NEW ZEALAND IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 53 ASEAN COUNTRIES IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 54 REST OF APAC IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 55 LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 56 BRAZIL IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 57 HEALTHCARE SPENDING IN MEXICO 2014 AND 2040 ($ BILLION)
FIGURE 58 MEXICO IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 59 HEALTHCARE SPENDING IN ARGENTINA 2014 AND 2040 ($ BILLION)
FIGURE 60 ARGENTINA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 61 CHILE IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 62 HEALTHCARE EXPENDITURE IN CHILE 2005-2016 (PERCENTAGE SHARE OF GDP)
FIGURE 63 HEALTHCARE SPENDING IN CUBA (2014 AND 2040)
FIGURE 64 CUBA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 65 REST OF LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 66 MIDDLE EAST AND NORTH AFRICA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 67 SAUDI ARABIA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 68 TURKEY IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 69 UNITED ARAB EMIRATES IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 70 SOUTH AFRICA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)
FIGURE 71 REST OF MIDDLE EAST AND AFRICA IMMUNOHISTOCHEMISTRY MARKET 2019-2027 ($ MILLION)